SCHEMBL5565462

SCHEMBL5565462

O=C(CNC(=O)C(c1ccc(Cl)cc1)c1ccc(-n2ncc(=O)[nH]c2=O)cc1Cl)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 11/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NR1I2 O75469 1/20 0.46
ABCB11 O95342 1/20 0.45
THRB P10828 2/20 0.38
HSD11B1 P28845 2/20 0.38
ESR1 P03372 1/20 0.36
POLB P06746 1/20 0.36
TSHR P16473 1/20 0.36
DNMT1 P26358 1/20 0.36
THRA P10827 1/20 0.35
CNR1 P21554 1/20 0.35
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5566945 0.91 MEN1 (0.52) P2RX7MEN1KMT2ANR1I2ABCB11
SCHEMBL5567087 0.86 MEN1 (0.47) P2RX7MEN1KMT2ANR1I2ABCB11
SCHEMBL10394520 0.83 MEN1 (0.53) P2RX7MEN1KMT2ANR1I2ABCB11
SCHEMBL6490492 0.82 MEN1 (0.56) P2RX7MEN1KMT2ANR1I2ABCB11
SCHEMBL6487104 0.81 P2RX7 (0.51) P2RX7MEN1KMT2ANR1I2ABCB11
SCHEMBL5566005 0.81 MEN1 (0.45) P2RX7MEN1KMT2ANR1I2ABCB11
SCHEMBL5567160 0.81 MEN1 (0.56) P2RX7MEN1KMT2ANR1I2ABCB11
SCHEMBL5566846 0.81 MEN1 (0.50) P2RX7MEN1KMT2ANR1I2ABCB11
SCHEMBL9823423 0.80 MEN1 (0.55) P2RX7MEN1KMT2ANR1I2ABCB11
SCHEMBL9823506 0.79 MEN1 (0.53) P2RX7MEN1KMT2ANR1I2ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1000040-B1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2007-06-13 EP disclosed
US-20050090495-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs LACRAMPE JEAN FERNAND ARMAND (FR) 2005-04-28 US disclosed
US-6867207-B2 IL-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-03-15 US disclosed
US-20040167333-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs LACRAMPE JEAN FERNAND ARMAND (FR) 2004-08-26 US disclosed
US-20020072603-A1 Novel IL-5 inhibiting 6-azauracil derivatives LACRAMPE JEAN FERNAND ARMAND (FR) 2002-06-13 US disclosed
EP-1000040-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-05-17 EP disclosed
WO-1999002505-A1 IL-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1999-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167333-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs IL6ST, CXCR5, ALOX5 P2RX7 316/4885MEN1 4239/4885KMT2A 4336/4885
US-20050090495-A1 Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs CXCR5, HCAR3, IL6ST P2RX7 274/4885MEN1 3111/4885KMT2A 4590/4885
US-20020072603-A1 Novel IL-5 inhibiting 6-azauracil derivatives IL6ST, ALOX5, IL5 P2RX7 713/4885MEN1 4683/4885KMT2A 3274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.